Surbhi Sarna, CEO and founder of Collate, discussed her company's AI-native software that automates documentation for life-sciences companies bringing drugs and devices to market. The GxP-compliant platform maintains human oversight for audits. Sarna's journey into healthcare technology began as a teenager when she was hospitalised with debilitating ovarian cysts, facing uncertainty about whether she had cancer. This experience motivated her to found nVision Medical, which was later acquired by Boston Scientific. Collate addresses the extensive documentation requirements in the pharmaceutical and medical device industries, streamlining regulatory compliance processes whilst ensuring proper human verification remains in place.

AI startup Collate has raised $95 million in a Series C round led by Redpoint Ventures, valuing the company at nearly $1 billion. The funding brings total capital raised to $125 million since the San Francisco-based company emerged from stealth 17 months ago. Founded by two-time entrepreneur and former Y Combinator partner Surbhi Sarna, Collate automates paperwork for life sciences companies, including regulatory filings and clinical trial documentation. The startup has signed approximately 50 customers since May 2025, including major pharmaceutical companies and medical device manufacturers. Collate's AI tools deliver time savings of 50% to 90% on documents that previously took months to complete, whilst maintaining accuracy above 90%. The company requires human verification before documents are exported to ensure patient safety.